GlassScriptPhysician profile
Inna Tubman
NPI 1417018623
$6,067.63
in general payments reported to CMS, 2019-2025
38 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $882 · 2020: $655 · 2021: $753 · 2022: $1,090 · 2023: $940 · 2024: $587 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,647 · Education: $40.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,646.54 |
| Education | $40.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $1,083.06 | 2019-2025 | Slynd |
| Abbvie INC. | $747.88 | 2019-2025 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $543.42 | 2021-2025 | |
| Evofem Biosciences, INC. | $381.11 | 2021-2025 | Phexxi, Solosec, Phexx |
| Hologic Sales and Service, LLC | $358.95 | 2019-2024 | Myosure Tissue Removal Device, Novasure, Fluent Fluid Management System |
| Pfizer INC. | $324.58 | 2019-2025 | |
| Millicent US INC | $276.36 | 2019-2025 | Femring, Intrarosa, Femlyv |
| Astellas Pharma US INC | $258.07 | 2023-2025 | Veozah |
| Therapeuticsmd, INC. | $194.90 | 2019-2022 | |
| Lupin INC. | $174.01 | 2019-2020 | |
| Organon LLC | $154.88 | 2022-2025 | Nexplanon, Jada System |
| Agile Therapeutics, INC. | $148.84 | 2021-2023 | Twirla |
| Scynexis, INC. | $147.81 | 2022 | |
| Avion Pharmaceuticals | $118.41 | 2019-2023 | Balcoltra |
| Roche Diagnostics Corporation | $104.98 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $99.78 | 2022 | |
| Myovant Sciences INC. | $76.19 | 2021-2022 | |
| Shield Therapeutics INC | $72.92 | 2023-2025 | Accrufer |
| Myriad Women'S Health, INC. | $70.76 | 2023 | Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $66.32 | 2020-2022 | |
| Meditrina | $65.24 | 2022-2025 | |
| Intra-Sana Laboratories | $64.80 | 2024-2025 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Minerva Surgical, INC | $61.22 | 2022-2024 | |
| Coopersurgical, INC. | $57.90 | 2021-2025 | Paragard T 380a |
| Sumitomo Pharma America, INC. | $50.61 | 2025 | Gemtesa |
| Duchesnay USA Incorporated | $48.64 | 2019 | |
| Merck Sharp & Dohme LLC | $43.88 | 2019-2020 | |
| Allergan, INC. | $38.33 | 2019-2020 | |
| Amgen INC. | $37.98 | 2020-2022 | |
| Amag Pharmaceuticals, INC. | $35.61 | 2019 | |
| Exact Sciences Corporation | $33.04 | 2025 | Cologuard Collection Kit |
| Vertical Pharmaceuticals, LLC | $23.46 | 2019 | |
| Dexcom, INC. | $22.05 | 2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $21.12 | 2023 | Wegovy |
| Currax Pharmaceuticals LLC | $16.59 | 2025 | Contrave |
| Aspira Women'S Health INC | $16.20 | 2020 | |
| Mycovia Pharmaceuticals, INC. | $15.68 | 2023 | Vivjoa |
| Novum Pharma, LLC | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inna Tubman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.